Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B'
American Resolve Action Senior Fellow on 340B reform: Oversight 'could prevent billions of dollars in annual waste, fraud, and abuse'
Community Oncology Alliance Executive Director Okon on 340B: ‘Expanding participation in a flawed program isn’t reform’
Pritchett Policy Associates founder Pritchett on biosimilar access: 'PBMs are the problem not patents'
Paragon Health Institute links ACA and HRSA to 340B program growth, calls for reforms
Alerts Sign-up
